# A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

> **NCT06282159** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dianthus Therapeutics** · enrollment: 65 (actual)

## Conditions studied

- Myasthenia Gravis, Generalized

## Interventions

- **DRUG:** DNTH103
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06282159
- **Lead sponsor:** Dianthus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-23
- **Primary completion:** 2025-07-28
- **Final completion:** 2027-08
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06282159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06282159, "A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06282159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*